Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neuphoria Therapeutics (NEUP) Invested Capital (2020 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Invested Capital for 5 consecutive years, with $29.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Invested Capital rose 116.04% to $29.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $29.7 million, a 116.04% increase, with the full-year FY2025 number at $19.0 million, changed N/A from a year prior.
  • Invested Capital was $29.7 million for Q4 2025 at Neuphoria Therapeutics, up from $12.5 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $40.8 million in Q2 2022 to a low of $12.5 million in Q3 2025.
  • A 4-year average of $22.6 million and a median of $20.6 million in 2025 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: crashed 45.65% in 2023, then soared 116.04% in 2025.
  • Neuphoria Therapeutics' Invested Capital stood at $40.8 million in 2022, then crashed by 45.65% to $22.2 million in 2023, then tumbled by 37.95% to $13.7 million in 2024, then skyrocketed by 116.04% to $29.7 million in 2025.
  • Per Business Quant, the three most recent readings for NEUP's Invested Capital are $29.7 million (Q4 2025), $12.5 million (Q3 2025), and $19.0 million (Q2 2025).